Friday, February 20, 2026

Symposium Agenda

Details are still being finalized

Session 1: Cardiomyopathy—Genotypes, Phenotypes & Endotypes

  • Have We Yet Achieved Precision Therapy in HCM?

    Martin S. Maron, MD
    8:45 AM

  • HCM: Updates in Clinical Therapies

    Ahmad Masri, MD, MS
    8: 55 AM

  • Understanding Incomplete Penetrance in Cardiomyopathies – Insights from Novel Models

    Eric D. Adler, MD, FACC
    9:05 AM

  • Understanding Titin Cardiomyopathy

    Zoltan P. Arany, MD, PhD
    9:15 AM

  • The True Guide to Precision Care: Genotype, Endotype, or Phenotype?

    DISCUSSION PANEL W/ MODERATOR
    9:25 AM

Session 2: The Genetic Revolution is Here, Or is It?

  • With All This Sequencing, What Have We Learned?

    Victoria Parikh, MD
    9:55 AM

  • Genetic Testing of Hyperlipidemia

    Samuel Tsimikas, MD, FAHA, FACC, FSCAI
    10:05 AM

  • Treatment of LPA

    Harpreet Bhatia, MD, MAS
    10:15 AM

  • The Why, Who, What, and How of Genetic Screening for Heart Failure: Polygenic Risk Scores—Are They Useful?

    Quan Bui, MD
    10:25 AM

  • Why Aren’t We Testing More Patients? Should We?

    DISCUSSION PANEL W/ MODERATOR
    10:35 AM

Session 3: Unraveling ATTR—Pathophysiology, Imaging & Intervention

  • Transthyretin Amyloidosis Pathophysiology: Why is There Destabilization and What Drives Organ Infiltration?

    Marcus A. Urey, MD
    11:20 AM

  • Imaging for Diagnosis and Surveillance - Can We Rely on Novel Imaging Tools to Quantify Amyloid Burden?

    Brett W. Sperry, MD
    11:30 AM

  • Disease Targeted Therapies - Can Early Diagnosis and Treatment Initiation Halt Disease Progression?

    Ahmad Masri, MD, MS
    11:40 AM

  • Stabilizers, Silencers, or Antibodies - Which is First Line?

    DISCUSSION PANEL W/ MODERATOR
    11:50 AM

Therapeutics for Genetic Disorders

LUNCH // SPONSORED LECTURE
12:20 PM

Session 4: Therapeutic Platforms

  • KEYNOTE: Economics of Innovation – Who’s Paying and Who’s Benefiting from Precision Cardiac Care?

    Robert M. Califf, MD, MACC
    1:30 PM

  • Challenges In and Strategies to Improve Rare Disease Health Technology Assessments

    Daniel A. Ollendorf, PhD
    1:50 PM

  • Valuation of Rare Disease Therapeutics Using Real World Evidence

    Michael Hogarth, MD
    2:00 PM

  • Partnerships for Progress: Funding the Innovation Engine, Looking Beyond the NIH

    PANEL w/ Moderator
    2:10 PM

  • Overview of Ex Vivo Gene Therapy for Genetic Disorders

    Stephanie Cherqui, PhD
    2:40 PM

  • Overview of Gene Therapies

    Kimberly N. Hong, MD
    2:50 PM

  • RNA: ASO, siRNA, and Gene Editing

    Gene W. Yeo, PhD, MBA
    3:00 PM

  • On Capsids and Constructs: Lessons from Gene Therapy for Skeletal Myopathy

    Alan H. Beggs, PhD
    3:10 PM

  • RNA, DNA, or Protein: Where Should We Focus Our Investments?

    DISCUSSION PANEL W/ MODERATOR: Joshua Schimmer, MD
    3:20 PM

Session 5: Devices & AI in Heart Failure

  • Artificial Intelligence for Risk Prediction: An Overview

    Avraham Yagil, PhD
    4:05 PM

  • Generative AI for Healthcare Operations

    Karendeep Singh, MD
    4:15 PM

  • Devices for Heart Failure: 2025 and Beyond

    Hao Howie Tran, MD
    4:25 PM

  • Predicting Rejection in Heart Transplantation

    SPEAKER TBD
    4:35 PM

  • Why Is It Taking So Long for AI to Transform Medicine?

    PANEL w/ Moderator
    4:45 PM

  • Closing Remarks

    Eric D. Adler, MD, FACC
    5:15 PM

POST-SYMPOSIUM MIXER

Details Coming
6:00 PM